The estimated Net Worth of Michael John Tomsicek is at least $4.73 Milhão dollars as of 19 October 2022. Mr. Tomsicek owns over 15,000 units of CRISPR Therapeutics AG stock worth over $681,600 and over the last 9 years he sold CRSP stock worth over $0. In addition, he makes $4,043,990 as Chief Financial Officer at CRISPR Therapeutics AG.
Michael has made over 5 trades of the CRISPR Therapeutics AG stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 15,000 units of CRSP stock worth $79,800 on 19 October 2022.
The largest trade he's ever made was exercising 25,000 units of CRISPR Therapeutics AG stock on 6 August 2021 worth over $443,750. On average, Michael trades about 2,906 units every 35 days since 2015. As of 19 October 2022 he still owns at least 15,000 units of CRISPR Therapeutics AG stock.
You can see the complete history of Mr. Tomsicek stock trades at the bottom of the page.
Michael John Tomsicek serves as Chief Financial Officer of the Company. Prior to joining our company, Prior to joining our company, Mr. Tomsicek served as Chief Financial Officer of Abiomed, a publicly-traded provider of medical devices, from July 2015 to August 2017. Before that, Mr. Tomsicek was Senior Vice President, Chief Financial Officer at Cubist Pharmaceuticals. He was at Cubist from August 2010 to January 2015 (through its sale to Merck) and held a series of roles of increasing responsibility leading finance, investor relations and strategic sourcing through a period of dynamic growth at the company. Prior to Cubist, Mr. Tomsicek spent nearly eight years at General Electric Healthcare, as finance manager in global operations, and then as chief financial officer of its ultrasound business. Mr. Tomsicek holds a BS in engineering and an MBA, both from the University of Wisconsin.
As the Chief Financial Officer of CRISPR Therapeutics AG, the total compensation of Michael Tomsicek at CRISPR Therapeutics AG is $4,043,990. There are 4 executives at CRISPR Therapeutics AG getting paid more, with Samarth Kulkarni having the highest compensation of $16,265,700.
Michael Tomsicek is 54, he's been the Chief Financial Officer of CRISPR Therapeutics AG since 2017. There are 3 older and 9 younger executives at CRISPR Therapeutics AG. The oldest executive at CRISPR Therapeutics AG is Katherine High, 68, who is the Independent Director.
Michael's mailing address filed with the SEC is C/O MILESTONE PHARMACEUTICALS INC., 1111 DR. FREDERIK-PHILIPS BLVD, STE 420, MONTREAL, A8, H4M 2X6.
Over the last 8 years, insiders at CRISPR Therapeutics AG have traded over $284,003,967 worth of CRISPR Therapeutics AG stock and bought 3,347,446 units worth $53,410,590 . The most active insiders traders include Plc Gsk, Ali Behbahani, eCorp /De/ Celgene. On average, CRISPR Therapeutics AG executives and independent directors trade stock every 13 days with the average trade being worth of $2,405,548. The most recent stock trade was executed by Julianne Bruno on 20 June 2024, trading 7,000 units of CRSP stock currently worth $318,080.
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.
CRISPR Therapeutics AG executives and other stock owners filed with the SEC include: